Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 17/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131062 | 1.00 | CMA1 (0.55) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998176 | 0.97 | CMA1 (0.55) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998173 | 0.97 | CMA1 (0.55) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL4135534 | 0.95 | CMA1 (0.54) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL4135544 | 0.95 | CMA1 (0.54) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998930 | 0.94 | CMA1 (0.55) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL997597 | 0.91 | CMA1 (0.57) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999032 | 0.90 | CMA1 (0.51) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999028 | 0.90 | CMA1 (0.51) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL1000031 | 0.90 | CMA1 (0.56) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885PRSS1 72/4885PRSS2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.